Intercept Pharmaceuticals, Inc.
(NASDAQ : ICPT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 1.71%30.2614.1%$178.05m
AMRNAmarin Corp. Plc -0.75%19.911.7%$159.55m
AXSMAxsome Therapeutics, Inc. -2.31%90.341.9%$129.63m
SAVACassava Sciences, Inc. -4.40%8.250.0%$91.12m
ARQLArQule, Inc. 0.15%20.000.6%$78.96m
BHCBausch Health Cos., Inc. 1.71%30.260.0%$74.96m
SAGESAGE Therapeutics, Inc. 3.12%76.408.6%$70.78m
GWPHGW Pharmaceuticals Plc -0.13%118.976.2%$70.43m
JAZZJazz Pharmaceuticals Plc -0.36%151.052.3%$67.88m
ICPTIntercept Pharmaceuticals, Inc. -3.76%106.1116.9%$63.50m
PRGOPerrigo Co. Plc -0.82%59.026.8%$58.61m
HZNPHorizon Therapeutics Plc 0.29%38.406.6%$57.70m
ENDPEndo International Plc -2.27%6.048.8%$42.46m
ICLRICON plc 0.38%175.784.2%$41.39m
CTLTCatalent, Inc. -1.03%60.842.4%$37.19m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.